Knights of Columbus Asset Advisors LLC Lowers Stock Position in Adaptive Biotechnologies Corporation $ADPT

Knights of Columbus Asset Advisors LLC cut its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 28.3% in the fourth quarter, HoldingsChannel reports. The fund owned 137,330 shares of the company’s stock after selling 54,077 shares during the period. Knights of Columbus Asset Advisors LLC’s holdings in Adaptive Biotechnologies were worth $2,230,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC lifted its holdings in Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after purchasing an additional 1,565 shares in the last quarter. Assetmark Inc. increased its stake in shares of Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares in the last quarter. Smartleaf Asset Management LLC raised its position in shares of Adaptive Biotechnologies by 593.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock valued at $59,000 after purchasing an additional 3,371 shares during the period. Clearstead Advisors LLC raised its position in shares of Adaptive Biotechnologies by 1,545.6% during the 4th quarter. Clearstead Advisors LLC now owns 3,752 shares of the company’s stock valued at $61,000 after purchasing an additional 3,524 shares during the period. Finally, Caxton Associates LLP bought a new position in Adaptive Biotechnologies in the 1st quarter worth $93,000. 99.17% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Adaptive Biotechnologies

In other news, CFO Kyle Piskel sold 3,115 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $13.04, for a total transaction of $40,619.60. Following the completion of the sale, the chief financial officer directly owned 256,725 shares of the company’s stock, valued at approximately $3,347,694. The trade was a 1.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Chad M. Robins sold 37,263 shares of Adaptive Biotechnologies stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $15.19, for a total transaction of $566,024.97. Following the sale, the chief executive officer owned 2,180,518 shares of the company’s stock, valued at $33,122,068.42. The trade was a 1.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 2,237,392 shares of company stock worth $31,269,192. 5.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. JPMorgan Chase & Co. decreased their price target on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. TD Cowen upped their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, Piper Sandler set a $21.00 price objective on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $19.57.

Adaptive Biotechnologies Stock Performance

Shares of Adaptive Biotechnologies stock opened at $15.19 on Friday. Adaptive Biotechnologies Corporation has a one year low of $9.05 and a one year high of $20.76. The stock has a market cap of $2.43 billion, a price-to-earnings ratio of -46.03 and a beta of 2.16. The stock has a 50 day moving average price of $13.88 and a 200-day moving average price of $15.55.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. The firm had revenue of $70.87 million during the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The business’s revenue was up 35.1% on a year-over-year basis. During the same quarter last year, the business earned ($0.20) EPS. Sell-side analysts predict that Adaptive Biotechnologies Corporation will post -0.48 earnings per share for the current fiscal year.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.